New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 26, 2010
10:54 EDTMYL, FRX, TEVA, WPI, PFEPfizer may obtain compensation from Teva following court verdict
A federal court jury found on Friday that Pfizer's (PFE) patent for a drug known as Protonix is valid. Generic versions of Protonix, which are currently made by Israel's Teva (TEVA), India's Sun Pharma, and a company called Prasco, are used to treat ulcers. Most of the worldwide revenue from the generic version of the drug is currently obtained by Teva. In a note to investors, Cowen analysts predicted that Teva would have to pay compensation of about $400M to Pfizer. Teva was not willfully infringing the patent, since it had received a favorable preliminary injunction on the matter, and consequently would not be liable for triple damages, Cowen contends. The firm recommends that investors buy Teva on weakness today. Meanwhile, Citigroup analysts predict that the court would force Teva to pay about $652M in damages to Pfizer, but the firm predicts that such a verdict would reduce the Israeli company's 2010 profits by only $350M. However, the firm, which reiterates a Buy rating on Teva and a Hold rating on Pfizer, expects the companies to settle the matter out of court. On the other hand, Teva added that the judge could overturn the jury's verdict and invalidate Pfizer's patent. In mid-morning trading, Teva lost 1.10, or 1.78%, to $60.44, while Pfizer inched up 2c to $16.93.
News For PFE;TEVA;MYL;WPI;FRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
August 26, 2015
05:56 EDTTEVAStocks with implied volatility below IV index mean; BBY TEVA
Subscribe for More Information
August 25, 2015
17:11 EDTTEVAU.S. District Court rules in Eli Lilly's favor on Alimta vitamin regimen patent
Subscribe for More Information
15:02 EDTTEVA, MYLMylan says USPTO institutes IPR of two Copaxone patents
Subscribe for More Information
14:40 EDTMYL, TEVATeva Copaxone patents to be reconsidered by regulators, Bloomberg says
14:16 EDTPFE, MYLMylan launches generic version of Pfizer's Zosyn Injection
Mylan (MYL) announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials, which is the generic version of Pfizer's (PFE) Zosyn Injection. This product is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of certain bacteria. Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials had U.S. sales of approximately $72.1M for the 12 months ending June 30, 2015, according to IMS Health. Mylan's launch of this product adds to the company's growing portfolio of more than 145 injectable products available to patients in the U.S. across a broad array of therapeutic categories including oncology, anti-infectives, anesthesia/pain management and cardiovascular.
13:22 EDTMYLMylan comments on 'misleading' Perrigo statements
Subscribe for More Information
11:27 EDTMYL, TEVATeva to refrain from voting at Mylan special meeting
Subscribe for More Information
08:17 EDTTEVATeva multiple low, says Leerink
Subscribe for More Information
August 24, 2015
12:57 EDTPFEFTC requires Pfizer to sell rights to four products as condition of buying Hospira
Subscribe for More Information
10:20 EDTTEVATeva says EMA confirms validation of reslizumab MAA
Subscribe for More Information
08:16 EDTPFEBristol-Myers, Pfizer to present new data on Eliquis at ESC Congress 2015
Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) announced that 22 abstracts will be presented at the ESC Congress 2015, to be held August 29 to September 2 in London, United Kingdom. The new data reinforce the Alliance's commitment to the ongoing evaluation of Eliquis in both the nonvalvular atrial fibrillation and venous thromboembolism patient populations. In addition, data from the AEGEAN study evaluating adherence among NVAF patients further extends the Alliance's commitment to patient care.
08:01 EDTPFEPfizer receives clearance from FTC for Hospira acquisition
Subscribe for More Information
August 23, 2015
12:35 EDTPFEBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
15:22 EDTMYLMylan clarifies certain inaccuracies related to lowered condition to acquire Perrigo
Subscribe for More Information
08:19 EDTMYLMylan to host special shareholder meeting
Subscribe for More Information
08:01 EDTPFEPfizer says two Phase 3 Trumenba studies met primary endpoints
Subscribe for More Information
05:51 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Stocks with implied volatility below IV index mean; Teva (TEVA) 25, Keurig Green Mountain (GMCR) 39 according to iVolatility.
August 20, 2015
11:24 EDTPFEPfizer says Ibrance application validated by EMA
Subscribe for More Information
05:58 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Stocks with implied volatility below IV index mean; Teva (TEVA) 23, Keurig Green Mountain (GMCR) 37 according to iVolatility.
05:57 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use